Shionogi Data Shows Cefiderocol Effective Against Resistant Enterobacterales Infections
Event summary
- Shionogi presented real-world data on Fetroja®/Fetcroja® (cefiderocol) at ESCMID Global 2026, showing 68% clinical cure rate in MBL-producing Enterobacterales infections.
- The CIRCE study involved 232 patients in Spain, with 82% achieving clinical response at day 14 and 83% survival at day 28.
- Cefiderocol demonstrated microbiological eradication rates of 85% in bloodstream infections and 82% in urinary tract infections.
- Additional data showed consistent in vitro activity against Stenotrophomonas maltophilia over a 10-year period.
The big picture
Shionogi's data reinforces cefiderocol's role in combating antimicrobial resistance, particularly against high-priority pathogens like MBL-producing Enterobacterales. The findings come as global health systems face increasing challenges from drug-resistant infections, positioning Shionogi as a key player in the antimicrobial space. The company's partnerships with GARDP and CHAI further underscore its commitment to expanding access to critical antibiotics.
What we're watching
- Clinical Adoption
- How the real-world effectiveness data will impact prescribing patterns for cefiderocol in critical care settings.
- Regulatory Dynamics
- Whether the positive data will accelerate approvals or expand indications in key markets.
- Competitive Positioning
- The pace at which Shionogi can differentiate cefiderocol against emerging therapies for resistant Gram-negative infections.
Related topics